NOS3 and metabolic disease: Thus, miR-34a, miR-217, and miR-383, which are upregulated in atherosclerotic lesions, obesity, and diabetes, are known to target SIRT1, which in turn is an important regulator of metabolic disorders by promoting eNOS transcription and activity [33, 146, 153, 155].